Administration of phthalates is known to cause toxicity and liver cancer in rodents through the activation of peroxisome proliferatoractivated receptors (PPARs), and the monoesters appear to be the active metabolites that function as ligands of PPARs. There is evidence that PPARs exhibit significant species differences in response to ligand activation. In this study, the activation of mouse and human PPARa, PPARb, and PPARg by a broad class of phthalate monoesters was investigated using a trans-activation assay, functional analysis of PPARa target gene expression, and a PPARg-mediated differentiation assay. These studies demonstrated a range in the ability of various phthalate monoesters to activate PPARa, with the mouse PPARa generally being activated at lower concentrations and exhibiting a greater response than human PPARa. Similarly, a range in the trans-activation of mouse PPARb by phthalate monoesters was also observed, but this effect was not found with human PPARb. A number of phthalate monoesters activated both mouse and human PPARg, with similar sensitivity being exhibited by both receptors. These studies show that the potency and efficacy of phthalate monoesters for the activation of PPARa and PPARg increase with increasing sidechain length. These studies also show that mouse PPARa and PPARb are generally activated at lower concentrations of phthalate monoesters than human PPARa and PPARb, and that both mouse and human PPARg exhibit similar sensitivity to phthalate monoesters. Lastly, there is a good relationship between the relative ability of phthalate monoesters to trans-activate PPARa and PPARg, and the relative induction of PPARa target gene mRNA and PPARg-mediated adipocyte differentiation, respectively.
Phthalate diesters are chemicals that are widely used, primarily as plasticizers in the manufacture of flexible vinyl products including medical devices as well as in some nonvinyl products including cosmetics (Blass, 1992) . Phthalate diesters can leach from vinyl products and enter the surrounding environment. Recent examination of urinary levels of phthalate monoesters in a United States reference population indicated human exposure to several phthalate monoesters (Blount et al., 2000; Kato et al., 2004; Silva et al., 2004) . The phthalate monoesters with the highest urinary levels were monoethyl phthalate (MEP; 9,463 ppb), monobenzl phthalate (MBenP; 464 ppb), and monobutyl phthalate (MButP; 306 ppb). Human exposure to phthalates is due primarily to ingestion of food contaminated from environmental sources (Kavlock et al., 2002a,b,c) , although inhalation of airborne or dust-associated phthalates may also occur (Adibi et al., 2003) . Dermal contact with products containing phthalates can also contribute to exposure, although high-molecular-weight phthalates are very poorly absorbed (Elsisi et al., 1989) . Once ingested or otherwise absorbed, phthalate diesters are hydrolyzed to the corresponding monoesters by esterases in the liver and blood and by pancreatic lipases in the gastrointestinal tract (Huber et al., 1996) .
Many of the adverse effects, including hepatocarcinogenesis, induced by monoesters of high-molecular-weight phthalates (e.g., !C6 side-chains) in rodents are thought to be mediated by peroxisome proliferator-activated receptors (PPARs) (Doull et al., 1999) . PPARs are members of the nuclear receptor superfamily and consist of three isoforms, namely PPARa, PPARb(d), and PPARg (Shearer and Hoekstra, 2003) . In response to ligand activation, PPARs heterodimerize with retinoid-X-receptor-a (RXRa), interact with co-activators and peroxisome proliferator-response elements (PPREs) found in the promoter region of target genes, and modulate expression of target genes (Shearer and Hoekstra, 2003) . Specific ligands have been identified for all three PPARs. For example, a broad class of chemicals collectively referred to as peroxisome proliferators (e.g., the fibrate class of hypolipidemic drugs, endogenous and dietary fatty acids, herbicides and phthalate monoesters), can all bind to, or specifically activate, PPARa (Berger and Moller, 2002) . Each PPAR participates in regulating biological functions through modulation of specific target genes.
PPARa regulates target genes that modulate fatty acid degradation, PPARg regulates target genes that modulate glucose homeostasis, and PPARb may regulate fatty acid metabolism in skeletal muscle (Berger and Moller, 2002; Fredenrich and Grimaldi, 2004; Wang et al., 2003) . There is also evidence that all three PPARs modulate carcinogenesis. PPARa is required to mediate hepatocarcinogenesis induced by peroxisome proliferators in rodents, and activation of PPARg has been shown to be anti-carcinogenic in a number of model systems, but the role of PPARb in carcinogenesis is unclear (Gupta et al., 2004; Harman et al., 2004; Michalik et al., 2004; Stephen et al., 2004) .
Previous work by others has shown that several phthalate monoesters (MEHP, MBenP, MButP) activate PPARa and PPARg, and that lower concentrations are required for activation of mouse PPARa than human PPARa (Hurst and Waxman, 2003; Maloney and Waxman, 1999) . The purpose of the present studies was three-fold: (1) to examine the ability of a broader class of phthalate monoesters and related substances of varying side-chain length and structures, to activate all three PPARs, (2) to determine if there is a species difference in receptor activation for this broader class of phthalate monoesters, and (3) to compare receptor activation observed in a trans-activation assay with PPAR-mediated biological changes, or PPAR-mediated alterations in target gene expression. It is important to point out that the broad class of monoesters examined for these studies represents the majority of commercially important phthalates.
MATERIALS AND METHODS
Chemicals. Mono-ethyl phthalate (MEP), mono-benzyl phthalate (MBenP), mono-isoheptyl phthalate (MIHP), mono-isononyl phthalate (MINP), mono-2-ethylhexyl adipate (MEHA), mono-isohexyl phthalate (MIHP2), mono-2-ethylhexyl phthalate (MEHP), mono-isodecyl phthalate (MIDP), and mono-n-octyl phthalate (MnOP) were synthesized by ChemSyn Laboratories (Lenexa, KS) and kindly provided by the Phthalate Esters Panel, American Chemistry Council. MButP was synthesized by Chem Service (West Chester, PA) and kindly provided by Dr. Kevin Gaido. Structures of the phthalate monoesters used for these studies are shown in Figure 1 . Wy-14,643 (4-chloro-6-(2,3xylidino)-2-pyrimidinythiol acetic acid) was purchased from ChemSyn Laboratories (Lenexa, KS). Troglitazone (Trog) was kindly provided by Dr. Takashi Yamoto (Sankyo, Shigouka, Japan). Dimethyl sulfoxide (DMSO) and tetradecylthioacetic acid (TTA) were purchased from Sigma Chemical Co. (St. Louis, MO).
Plasmids. The ligand-binding domain of mouse or human PPARa, PPARb, or PPARg was fused to the DNA-binding domain of the yeast transcription factor Gal4 under the control of the SV40 promoter. This plasmid also encoded the UAS-firefly luciferase reporter under the control of the Gal4 DNA response element.
Cell culture and trans-activation assay. Mouse 3T3-L1 fibroblasts (ATCC, Manassas, VA) were cultured in high-glucose Dulbecco's Minimal Essential Medium (DMEM) supplemented with 10% fetal bovine serum (FBS, Sigma, St Louis, MO), 0.2 mg/ml streptomycin and 200 U/ml penicillin (Gibco, Grand Island, NY) . Cells were transfected with plasmid DNA using Lipofectamine reagent (Invitrogen, Carlsbad, CA) and following the manufacturer's recommended procedures, using 3T3-L1 cells at approximately 80% confluence in 10-cm culture dishes. After 6 h, the DNA-Lipofectamine complex was removed, and the cells were maintained overnight in culture medium. Following overnight culture, the transfected 3T3-L1 cells containing chimeric mouse or human PPARa-LBD/Gal4-DBD-(PPARa-ligand binding domain/ Gal4-DNA binding domain), PPARb-LBD/Gal4-DBD-, or PPARg-LBD/ Gal4-DBD-Gal4 luciferase reporter plasmids were split to multiwell cluster plates. The media was replaced, 4 h after replating, with serum-free DMEM containing phthalate monoesters at concentrations of 3, 10, 30, 100, or 200 mM to evaluate PPAR activation. Solutions of phthalate monoesters and positive controls were prepared fresh on the day the cells were treated. Wy-14,643 (25 mM) was used as a positive control for the activation of PPARa, tetradecylthioacetic FIG. 1. Chemical structures of the phthalate monoesters tested for their ability to activate mouse and human PPARs. *The alkyl side-chains of these monoesters are isomeric with methyl branching. ACTIVATION OF MOUSE AND HUMAN PEROXISOME PROLIFERATOR BY PHTHALATE MONOESTERS acid (50 mM) was used as a positive control for PPARb activation, and troglitazone (3 mM) was used as a positive control for PPARg activation. Twenty-four h after the treatment of the transfected 3T3-L1 cells with phthalate monoesters, the cells were lysed at À20 C with passive lysis buffer (Promega, Madison, WI) for 30 min; luciferase activity was measured using the Luciferase reporter assay kit (Promega, Madison, WI) and a Turner TD-20/20 Luminometer (Turner BioSystems, Sunnyvale, CA) and manufacturer's recommended procedures. The protein concentration of the cell lysate was determined using the BCA protein assay kit (Pierce, Rockford, Illinois). Luciferase activity was normalized to the protein concentration of each sample. The fold induction of normalized luciferase activity was calculated relative to DMSO (vehicle)-treated cells, and represents the mean of three independent samples per treatment group.
Cell culture and Northern blot analysis of PPARa-dependent target mRNA induction in hepatoma cell lines. Rat hepatoma FaO cells were cultured in DMEM supplemented with 5% FBS, 100 units/ml of penicillin, and 100 mg/ml of streptomycin. Human hepatoma HepG2 cells were cultured in alpha Minimal Essential Medium (aMEM) supplemented with 5% FBS, 100 units/ml of penicillin, and 100 mg/ml of streptomycin. FaO and HepG2 cells were seeded in 6-well plates at 7 3 10 5 cells/well and treated for 48 h with either phthalate monoesters, DMSO (vehicle), or Wy-14,643 (100 mM). The test concentrations of phthalate monoesters were either 10 or 100 mM and corresponded to the lower or upper ends of the respective dose response curves obtained from the transactivation studies for those phthalate monoesters with significant PPARa activity. These concentrations were also used for phthalate monoesters that did not exhibit significant PPARa activity for comparative purposes. After treatment with the indicated phthalate monoester, total RNA was isolated using TRIZOL reagent (Invitrogen, Carlsbad, CA) and following the manufacturers recommended procedures. Five micrograms of total RNA were electrophoresed on 0.22 M formaldehyde denaturing agarose gel, transferred to a nylon membrane, and fixed using UV cross-linking. Membranes were hybridized in ULTRAhyb hybridization buffer (Ambion, Austin, TX) with random primed 32 P-labeled probes for known PPARa target genes including acyl-CoA oxidase (ACOX) and cytochrome P450 4A (CYP4A) or GAPDH (loading control) generated from the respective cDNA using Ready-To-Go DNA Labeling Beads (Amersham Biosciences, Piscataway, NJ) and following manufacturer's recommended procedures. Hybridization signals were obtained after scanning with a phosphorimager and were normalized relative to GAPDH. The fold induction of normalized ACOX and CYP4A mRNAs in both FaO and HepG2 cells were calculated relative to DMSO (vehicle)-treated cells and represent the mean of two independent samples per treatment group.
Cell culture and 3T3-L1 cell differentiation assay. Mouse 3T3-L1 fibroblasts were cultured in DMEM containing 10% FBS at 37 C/5% CO 2 . The fibroblasts were later trypsinized and seeded at approximately 50% confluence in 12-well plates. Adipogenesis was induced 48 h postconfluence, using a standard differentiation assay (Green and Meuth, 1974) . This consists of changing the culture medium to DMEM/4% FBS containing 1.0 mg/ml insulin, 1 mM dexamethasone, 100 mM isomethylbutylxanthine, and troglitazone (10 mM) or the indicated phthalate monoester and monitoring subsequent lipid accumulation. Four phthalate monoesters that had significant PPARg activity based on the transactivation studies were used, and two phthalate monoesters that had no significant PPARg activity were used for comparison. The media was replaced with DMEM/ 4% FBS containing 1.0 mg/ml insulin and troglitazone (10 mM), or the indicated phthalate monoester, every 48 h after the initiation of differentiation. The 3T3-L1 cells were fixed with formalin and stained with Oil Red O (Sigma Chemical Co, St. Louis, MO) 6 days after initiation of adipocyte differentiation. Briefly, cells were washed twice with phosphate buffered saline (PBS) and then fixed with formalin for 1 h at room temperature. The fixed cells were stained with Oil Red O (0.3 %) for 1 h. Cells were washed three times with water, visualized with a Nikon Eclipse microscope, and photographed.
Statistical analysis. Differences between treatments were determined using ANOVA followed by Dunnett's post hoc test (Prism 4.0, GraphPad Software, Inc., San Diego, CA). Significant differences were determined when p 0.05.
RESULTS

Activation of Mouse and Human PPARa, PPARb, and PPARg by Phthalate Monoesters
Phthalate monoesters of varying side-chain length and different structures were investigated for their ability to activate mouse and human PPARs. MEP, a C2 alkyl side-chain phthalate monoester ( Fig. 1) , did not consistently activate either mouse or human PPARa (Fig. 2) . MButP, a C3 alkyl side-chain phthalate monoester ( Fig. 1) , activated mouse PPARa at a concentration !100 mM, and human PPARa at a concentration of 200 mM (Fig. 2) . MBenP, which has a benzyl side-chain ( Fig. 1) , caused increased luciferase activity with concentrations !100 mM for mouse PPARa and with a concentration of 200 mM for human PPARa (Fig. 2) . MEHA, an adipic acid monoester of di-2-ethylhexyl adipate (DEHA; Fig. 1 ), caused increased luciferase activity with concentrations !100 mM for mouse PPARa (Fig. 2) . However, while a significant increase in luciferase activity was observed with a concentration of 100 mM MEHA with human PPARa, no difference in activity was observed with 200 mM MEHA for human PPARa (Fig. 2 ). MIHP2, a branched C6 (isohexyl) alcohol side-chain phthalate monoester ( Fig. 1) , caused a dose-dependent increase in luciferase activity with concentrations of !30 mM for mouse PPARa, in contrast to human PPARa, where an increase in luciferase activity was only observed with a concentration of 200 mM (Fig. 2) . MEHP, the active metabolite of the plasticizer di-2-ethylhexyl phthalate (DEHP), and MIHP, a branched C7 (isoheptyl) alcohol side-chain phthalate monoester ( Fig. 1) , caused a dose-dependent increase in luciferase activity with concentrations of !10 mM for mouse PPARa, and !30 mM for human PPARa (Fig. 2) . A dose-dependent increase in luciferase activity was observed for MnOP, a linear C8 alkyl side-chain phthalate monoester ( Fig. 1) , with concentrations of !10 mM for both mouse and human PPARa (Fig. 1 ). MINP, a branched C9 (isononyl) alcohol side-chain phthalate monoester ( Fig. 1) , caused a dose-dependent increase in luciferase activity with concentrations of !3 mM for mouse PPARa, while a dose-dependent increase in luciferase activity was only observed at concentrations !10 mM for human PPARa (Fig. 2) . MIDP, a branched C10 (isodecyl) alcohol side-chain phthalate monoester ( Fig. 1) , caused a dose-dependent increase in luciferase activity with concentrations of !3 mM for mouse PPARa (Fig. 1) , while a concentration of !30 mM was required to elicit a dose response for human PPARa (Fig. 2) . In general, lower concentrations of phthalate monoesters were required to activate mouse PPARa as compared to human PPARa, and the magnitude of the response was significantly greater for mouse PPARa than for human PPARa (Table 1) .
Phthalate monoesters did not activate human PPARb, although mouse PPARb was responsive to some of these chemicals. Similar to results observed for PPARa, MEP was ineffective at activating mouse PPARb-dependent luciferase 172 BILITY ET AL. activity (Fig. 3) . While a concentration of 3 mM MButP caused an increase in mouse PPARb-dependent luciferase activity, a dose-dependent increase in activity was only observed between 100 and 200 mM (Fig. 3) . Concentrations !100 mM of MBenP and MEHA were required to cause a dose-dependent increase in luciferase activity with the mouse PPARb construct, and concentrations !30 mM MIHP2 caused a similar dose-dependent increase in activity ( Fig. 3 ). MEHP and MIHP caused increases in luciferase activity with mouse PPARb, but only at a concentration of 200 mM (Fig. 3 ). MnOP and MIDP caused dose-dependent increases in mouse PPARb-dependent luciferase activity at a concentration !100 mM, while MINP was did not activate this PPAR isoform ( Fig. 3) . A comparative summary of these results is presented in Table 2 .
No change in mouse PPARg-dependent luciferase activity was observed for MEP, and although increased luciferase activity was observed using 10 mM MEP for human PPARgtransfected cells, no dose response was found ( Fig. 4 ). MButP did not cause any changes in luciferase activity using either mouse or human PPARg (Fig. 4 ). MBenP caused a dose-dependent increase in luciferase activity at a concentration !100 mM for mouse PPARg, while increased activity was only observed at a concentration of 200 mM for the human PPARg (Fig. 4) . Whereas concentrations !30 mM MEHA effectively increase luciferase activity using the mouse PPARg construct, no significant increases in activity were observed with MEHA using the human PPARg construct (Fig. 4) . Increased luciferase activity caused by MIHP2 was only observed at a concentration of 200 mM with mouse PPARg, and no change in activity was found when human PPARg was used ( Fig. 4 ). Increased luciferase activity was found using concentrations of MEHP ACTIVATION OF MOUSE AND HUMAN PEROXISOME PROLIFERATOR BY PHTHALATE MONOESTERS !30 mM with mouse PPARg, while concentrations !10 mM resulted in a dose-dependent increase in luciferase activity with human PPARg (Fig. 4) . Concentrations !100 mM MIHP were required to cause increased luciferase activity for both the mouse and human PPARg (Fig. 4) . MnOP caused a dose-dependent increase in luciferase activity at concentrations !10 mM and 100 mM for mouse and human PPARg, respectively (Fig. 4) . MINP and MIDP both caused a dose-dependent increase in mouse and human PPARg-dependent luciferase activity at concentrations of !3 and 30 mM, respectively (Fig. 4) . In general, comparable (yet moderately variable) concentrations of phthalate monoesters were required to effectively activate both mouse and human PPARg, and the magnitude of the response was essentially similar between both the mouse and human PPARg ( Table 3) .
Induction of PPARa-Dependent Target Gene mRNA in Rat Hepatoma FaO Cells and Human Hepatoma HepG2 Cells
The induction of mRNA encoding two PPARa target genes, acyl CoA oxidase (ACOX) and cytochrome P450 4A (CYP4A) was measured by Northern blot analysis, using RNA from rodent liver FaO cells and human liver HepG2 cells following treatment with phthalate monoesters, at concentrations ranging from the low and high end of the dose-response curves generated from trans-activation studies. Consistent with the results of the trans-activation studies, longer side-chain phthalate monoesters were more potent in inducing ACOX and CYP4A mRNAs than shorter side-chain phthalate monoesters in the rodent liver FaO cells (Fig. 5A) . Human liver HepG2 cells were nonresponsive to activation by phthalate monoesters for the induction of ACOX and CYP4A mRNA (Fig. 5B) . These results are consistent with the species difference exhibited by mouse and human PPARa in the trans-activation studies, where the magnitude of the response to phthalate monoesters was greater for mouse PPARa than human PPARa.
Induction of PPARg-Dependent Adipogenesis by Phthalate Monoesters
3T3-L1 fibroblasts terminally differentiate into adipocytes in a PPARg-dependent manner when treated with PPARg agonists in the presence of a differentiation cocktail consisting of dexamethasone, isobutylmethylxanthine, and insulin (Brun et al., 1996) . Lipid accumulation, indicative of PPARg-dependent adipogenesis, was measured using Oil Red O staining. Consistent with the results of the trans-activation studies for the activation of PPARg, the longer side-chain phthalate monoesters were more potent in inducing adipogenesis than the shorter side-chain phthalate monoesters (Fig. 6 ). Strong induction of adipogenesis was seen with MEHP, MINP, MIDP, and MnOP at 50 mM, while no induction of adipogenesis was seen with MButP and MBenP at 50 mM (Fig. 6 ).
DISCUSSION
This study was undertaken to characterize the hierarchy of potency for the activation of PPARs by a broad class of phthalate monoesters and the species differences between mouse and human PPARs for activation by this broad class of phthalate (50 mM) . The media was replaced with DMEM/4% FBS containing 1.0 mg/ml insulin and troglitazone (10 mM), or the indicated phthalate monoester every 48 h after initiation of differentiation. The cells were fixed 6 days after initiation of adipogenesis and stained with Oil Red O. Note, lipid accumulation, indicative of adipogenesis in cells treated with phthalate monoesters that had significant PPARg activity in the trans-activation studies, and the lack of lipid accumulation in samples treated with phthalate monoesters lacking significant PPARg activity in the trans-activation studies.
ACTIVATION OF MOUSE AND HUMAN PEROXISOME PROLIFERATOR BY PHTHALATE MONOESTERS more variability, due to differences in transfection efficiency and the requirement for other co-factors that could influence reporter activity. Based on results obtained with this model system, the hierarchy of potency for the activation of PPARa among the different phthalate monoesters was determined to be MnOP 4 (MIDP % MINP % MIHP) 4 (MEHP % MIHP2) 4 MBenP 4 MEHA 4 (MButP % MEP). These findings are relatively consistent with data from others examining the ability of MEHP, MBenP, MButP monomethyl, and mono-n-butyl to trans-activate mouse PPARa (Hurst and Waxman, 2003) . The activation potency for PPARa increased with increasing sidechain length of the phthalate monoesters, which is consistent with analysis for mouse PPARa by others (Lampen et al., 2003) . A significant species difference between receptor activation was observed, with mouse PPARa being activated by lower concentrations of phthalate monoesters and exhibiting greater luciferase activity as compared to human PPARa, which is also consistent with previous reports (Hurst and Waxman, 2003; Maloney and Waxman, 1999) .
There was a reasonably good association between the hierarchy of potency and species differences in PPARa activity and the induction of ACOX and CYP4A mRNAs in the hepatoma cell lines. For example, MEP and MButP did not effectively trans-activate mouse PPARa, and no changes in ACOX or CYP4A mRNA were detected in rat hepatoma FaO cells treated with these phthalate monoesters. In contrast, relatively good dose responses in mouse PPARa trans-activation were found for MIHP, MEHP, MnOP, MINP, and MIDP between 10 and 100 mM, and treatment of rat hepatoma FaO cells with these chemicals at these concentrations caused a dose-dependent induction of ACOX and CYP4A mRNAs. Others have shown that treating stably transfected rat hepatoma FaO cells expressing higher than endogenous levels of mouse PPARa with 10-300 mM MButP or MBenP causes dose-dependent increased expression of ACOX protein, but no significant differences in mRNA encoding ACOX (Hurst and Waxman, 2003) . Therefore, the results from the present studies are similar to previous reports, as no differences in ACOX mRNA levels were detected in response to either MButP or MBenP in rat hepatoma FaO cells. The reason why Hurst and Waxman (2003) detected higher levels of ACOX protein is uncertain, but could be due to higher than endogenous levels of mouse PPARa present in the cell line used for these studies. While marginally increased transactivation of human PPARa was observed at concentrations typically greater than 30 mM for some of the phthalate monoesters including MIHP, MEHP, MnOP, MINP, and MIDP, no changes in the level of mRNA encoding ACOX or CYP4A were found in HepG2 cells cultured in the presence of these chemicals at 10 or 100 mM. However, it is important to point out that, while statistically significant increases in reporter activity were observed for MIHP, MEHP, MnOP, MINP, and MIDP between 10 and 100 mM using the human PPARa construct, the fold increase was significantly smaller as compared to that observed using the mouse PPARa construct. Therefore, the lack of increases in PPARa target gene mRNA in human HepG2 cells as compared to rodent FaO cells is still relatively consistent with the species differences observed between the human and mouse trans-activation assay. This is also consistent with other reports demonstrating the lack of induction of PPARa target genes in HepG2 cells in response to peroxisome proliferators (Cornu-Chagnon et al., 1995; Duclos et al., 1997; Hsu et al., 2001; Lawrence et al., 2001; Savas et al., 2003) .
Previous studies have demonstrated significant differences in the response of humans and rodents to phthalates; rodents are generally sensitive, while humans and other primates are more refractory to the PPARa-mediated pathological effects of phthalates (Doull et al., 1999; Hall et al., 1999; Kamendulis et al., 2002; Klaunig et al., 2003; Kurata et al., 1998; Pugh et al., 2000) . Several investigators (Barber et al., 1987; Smith et al., 2000) have assessed the effects of a range of phthalates on rodent liver. The in vivo data are reasonably consistent with the in vitro PPARa trans-activation data in at least a qualitative sense; low-molecular-weight phthalates (e.g., 5C6 side-chains) have little effect on either liver weight or ACOX induction, whereas these effects are seen with the higher molecular weight species. Under in vivo conditions, the most active phthalates are DEHP, DINP, and DIDP. Interestingly, MnOP, which was the most active PPARa agonist with the in vitro trans-activation assay of the present study, does not appear to influence PPARadependent processes under in vivo conditions (Lake et al., 1984; Mann et al., 1985) . This is possibly due to rapid conversion of DnOP under in vivo conditions to lower-molecular-weight metabolites (Albro and Moore, 1974) . Results from the transactivation studies show that the mouse PPARa ligand-binding domain is generally more sensitive than its human counterpart to phthalate monoesters. Examination of PPARa target gene expression in a rodent and human liver cell line provides further evidence that rodents are more sensitive than humans to phthalate monoesters.Thereasonforthisapparentspeciesdifferenceisuncertain, but there is evidence that differences in expression levels of liver PPARa, mutations, or polymorphisms in target gene response elements, or mutant PPARa isoforms may contribute to this effect (Klaunig et al., 2003) . However, mice that express human PPARa in liver at similar levels to those reported in humans (in the absence of mouse PPARa expression) do not exhibit increased hepatocellular proliferation in response to a potent PPARa agonist (Cheung et al., 2004) . This suggests that there are likely fundamental structural differences in the PPARa (e.g., ability to recruit co-activators) that mechanistically explain the species differences observed after exposure to PPARa agonists such as phthalate monoesters.
Results from these studies have some relevance for human risk assessment, since humans are routinely exposed to phthalate monoesters, as shown by the presence of these compounds in human urine and serum Blount et al., 2000; Kato et al., 2004; Koch et al., 2003; Silva et al., 2004; Takatori et al., 2004) . Based on these studies, it is known that the urinary levels of the shorter side-chain phthalate monoesters are found at the higher levels (e.g., as high as $3800 ppb for MEP; 95th percentile) as compared to the longer side-chain phthalate monoesters (e.g., $500 ppb for MEHP; 95th percentile). Additionally, the concentration of total MEHP detected in urine and serum may be relatively comparable, although serum levels may actually be lower, since the current technology for measuring serum phthalate monoesters is hampered by the presence of these compounds in many of the reagents used for this analysis in addition to the presence of esterases in serum (Takatori et al., 2004) . In a pharmacokinetic study in rats, oral doses of 30, 500, and 1000 mg DEHP/kg were associated with peak blood concentrations of MEHP of 10, 210, and 390 mM, respectively (Kessler et al., 2004) , a concentration range similar to that used in the present studies. Rats administered DEHP orally in repeated administration studies exhibit significantly elevated liver weight and induction of ACOX at doses ranging from approximately 100 to 2000 mg/kg/day (Barber et al., 1987) . These observations, in addition to results obtained from the present studies, indicate that in rodents there is a qualitative relationship between effective concentrations under in vitro and in vivo conditions. Assuming the same relationship pertains to humans, blood concentrations similar to or higher than those that are effective in rodents, would be required to produce effective interactions with PPARa. However, data from the human population at large indicate that, at least under ambient conditions, blood concentrations are well below this range. Serum concentrations of MEHP in the U.S. population range from 2.8 to 15.2 ng/ml with a geometric mean of 3.9 ng/ml ($14 nM) (Kato et al., 2004) . Thus, at least for DEHP, the average concentration in humans is approximately three orders of magnitude below minimally effective in vitro concentrations capable of activating PPARa. Maximum serum levels of phthalate monoesters in humans within the general population are about two orders of magnitude below the effective concentrations required to activate PPARa. For example, the maximum serum concentrations of MEP, MBP, and MEHP in a reference U.S. human population are 73.3 (0.4 mM), 139.0 (0.6 mM) and 34.8 ng/ml (0.1 mM), respectively . Further, internal exposure to DEHP/MEHP can be much higher in patients undergoing some specific procedures, and in some cases the blood concentrations could reach $100 mM. Combined, these observations suggest that activation of PPARa is not likely to be a significant effect in response to phthalate monoester exposure in the general population, but is theoretically possible under certain conditions.
Results from the present studies also demonstrate that some phthalate monoesters can activate mouse PPARb, and that human PPARb appears to be less responsive to this effect. However, not all phthalate monoesters consistently activated PPARb. For example, no increase in PPARb-dependent reporter activity was detected in response to MEP, and the lack of a consistent dose-response curve for MIHP, MEHP, and MINP, within a known concentration range where solubility is not a confounding variable, suggests that these chemicals do not activate this PPAR isoform. In contrast, relatively good dose-response curves for mouse PPARb activation were found for MButP, MBenP, MIHP2, MIDP, and MnOP, and this effect was essentially lacking when the human PPARb isoform was used for transactivation. Additionally, the efficacy of activation was greater for MIHP2, MIDP, and MnOP as compared to the MButP and MBenP, suggesting that the phthalate monoesters with longer side-chains function better as PPARb ligands, similar to that observed for PPARa activation. Since isoC6, isoC10, and normal C8 side-chain monoesters effectively activated mouse PPARb, whereas isoC7, isoC8, and isoC9 side-chain monoesters were inactive, these data suggest that the structure-activity relationships are more subtle as compared to those observed for activation of PPARa. While others have shown that human PPARb can be activated by MEHP using a co-transfected reporter and PPAR constructs, a direct comparison with a mouse PPARb construct under these conditions was not provided (Lampen et al., 2003) . The reason for the difference between these results and the present studies cannot be determined from this work. The relevance of phthalate monoester exposure and PPARb activation is unclear. While results from the present trans-activation studies suggest that human PPARb would not likely be activated, data from another group suggests that human PPARb can be activated by MEHP (Lampen et al., 2003) . Interestingly, activation of PPARb is associated with both positive and negative biological effects. For example, there are recent reports that intestinal cancer and breast and prostate cancer cell line growth can be enhanced by treating with a PPARb ligand (Gupta et al., 2004; Stephen et al., 2004) ; however the specificity of these effects has not been examined in a null mouse model. In contrast, recent reports have also shown that PPARb ligands can enhance serum levels of HDL cholesterol (Oliver et al., 2001) , promote epithelial cell differentiation (Schmuth et al., 2004; Westergaard et al., 2001) , and in the absence of PPARb expression, skin and colon carcinogenesis is exacerbated Kim et al., 2004) . These results suggest that ligand activation of PPARb could function to prevent atherosclerosis and epithelial cancers. Therefore, until the specific biological function of PPARb is determined, the relevance of the present results is uncertain. However, based on observations made in the average human population described above, it is unlikely that human exposure would result in tissue concentrations capable of activating PPARb.
The hierarchy of potency observed in the trans-activation studies for the activation of PPARg by the phthalate monoesters was determined to be MnOP 4 MINP 4 (MIDP % MIHP) 4 (MEHP % MBenP % MEHA) 4 (MIHP2) 4 (MButP % MEP), with both species exhibiting similar responsiveness; this hierarchy also correlated well with the ability of the various phthalate monoesters to induce PPARg-dependent adipogenesis in 3T3-L1 fibroblast cell line. The hierarchy of potency and the similarity in species responsiveness for the activation of PPARg observed in this study is consistent with previous reports (Hurst and Waxman, 2003; Maloney and Waxman, 1999) . Similar to ACTIVATION OF MOUSE AND HUMAN PEROXISOME PROLIFERATOR BY PHTHALATE MONOESTERS the biological role of PPARb, the function of PPARg is unclear, as there are conflicting reports in the literature. PPARg agonists have been used for years as drugs to reduce blood glucose in type II diabetics, although the use of some agonists was associated with human mortality (Isley, 2003) . Additionally, several studies have suggested that activation of PPARg potentiates carcinogenic effects, as ligand treatment resulted in exacerbated carcinogenesis in APC min mice (Lefebvre et al., 1998; Saez et al., 1998) , and overexpression of an oncogene and a ligand-independent form of PPARg leads to exacerbated mammary tumorigenesis in bi-transgenic mice (Saez et al., 2004) . In contrast, other reports have shown that PPARg ligands can significantly reduce the number of aberrant crypt foci and colon polyps induced by azoxymethane in rats, inhibit growth of transplanted tumors in nude mice, and inhibit growth of colon tumor cell lines (reviewed in Michalik et al., 2004) . Additionally, tumor multiplicity is significantly greater in azoxymethanetreated heterozygous PPARg-null mice, and loss of function mutations are reported in human cases of colorectal cancer (reviewed in (Michalik et al., 2004) ). Therefore, while the present studies suggest that phthalate monoesters can activate both mouse and human PPARg, further research is needed to determine the biological relevance of PPARg activation that might occur in response to exposure to phthalate monoesters.
Lastly, while many ligands for PPARs (such as phthalate monoesters) function by activating specific PPARs, it is becoming increasingly clear that many ligands for nuclear receptors can be promiscuous and activate other nuclear receptors. Thus, while results from these studies demonstrate that phthalate monoesters can activate PPARs and that species differences exist in the ability to activate specific PPAR, it is still possible that these chemicals lead to events that are mediated by other nuclear receptors, and/or through events that are not dependent on receptor activation, per se, and this remains to be examined.
